Literature DB >> 640238

Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.

S A Ross, J Dupre.   

Abstract

Responses of plasma immunoreactive gastric inhibitory polypeptide (IRGIP) to oral triglyceride or galactose were compared in normal and mildly diabetic (non-insulin-dependent) subjects. After triglyceride the responses of IRGIP were similar, but after galactose those of the diabetics were slightly exaggerated. Both stimuli evoked increments of plasma immunoreactive glucagon (IRG) in diabetics but not in normal subjects. Plasma immunoreactive insulin (IRI) did not change. In normal subjects given oral triglyceride or galactose followed by intravenous (I.V.) glucose the early-phase response of plasma IRI was enhanced and glucose tolerance improved. In the diabetics, oral triglyceride did not affect insulin release or glucose tolerance after I.V. glucose; oral galactose elicited a slight increase of insulin release without improving glucose tolerance. In the diabetics the rise of plasma IRG after ingestion of triglyceride or galactose was maintained after I.V. glucose. It is concluded that endogenous GIP is insulinotropic and that there is partial resistance to this action in diabetes. The results were compatible with feedback inhibition of GIP secretion by insulin and with the suggestion that the rise of plasma IRG associated with secretion of GIP in diabetics may be due to the glucagonotropic action of this peptide.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 640238     DOI: 10.2337/diab.27.3.327

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  29 in total

1.  Comparison of glycemic response and insulin requirements after mixed meals of equal carbohydrate content in healthy, type-1, and type-2 diabetic man.

Authors:  J Schrezenmeir; F Tatò; S Tatò; E Küstner; U Krause; G Hommel; N G Asp; H Kasper; J Beyer
Journal:  Klin Wochenschr       Date:  1989-10-02

2.  Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase.

Authors:  Sameer Mohammad; Lavoisier S Ramos; Jochen Buck; Lonny R Levin; Francesco Rubino; Timothy E McGraw
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

4.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

5.  RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion.

Authors:  Cesar A Sommer; Gustavo Mostoslavsky
Journal:  Mol Endocrinol       Date:  2014-09-30

Review 6.  New developments in the incretin concept.

Authors:  W Creutzfeldt; R Ebert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

7.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

Authors:  I R Jones; D R Owens; A J Moody; S D Luzio; T Morris; T M Hayes
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

Authors:  P L McClean; N Irwin; K Hunter; V A Gault; P R Flatt
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

Review 10.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

Authors:  S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetologia       Date:  2013-02-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.